Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income: 2022-2025

Historic Net Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$30.9 million.

  • Taysha Gene Therapies' Net Income fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Net Income is -$30.9 million, which was down 23.92% from -$24.9 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Net Income peaked at -$15.0 million during Q4 2023, and registered a low of -$55.1 million during Q4 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Net Income value was -$20.1 million (recorded in 2025), while the average stood at -$21.3 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Net Income soared by 72.69% in 2023, and later tumbled by 43.36% in 2024.
  • Taysha Gene Therapies' Net Income (Quarterly) stood at -$55.1 million in 2022, then skyrocketed by 72.69% to -$15.0 million in 2023, then dropped by 21.39% to -$18.3 million in 2024, then fell by 29.62% to -$30.9 million in 2025.
  • Its Net Income stands at -$30.9 million for Q3 2025, versus -$24.9 million for Q2 2025 and -$20.1 million for Q1 2025.